New research suggests Alzheimer’s drugs may improve cognition by increasing Aβ42 levels rather than just reducing plaques, challenging the amyloid cascade hypothesis and pointing to new therapeutic strategies focused on restoring soluble Aβ42 to maintain brain health.
Leave a reply